POC Test Advances Hepatitis C Diagnosis
|
By LabMedica International staff writers Posted on 10 May 2017 |

Image: The Xpert HCV Viral Load cartridge, a quantitative test that provides on-demand molecular testing for confirmation of infection and monitoring of Hepatitis C virus (HCV) (Photo courtesy of Cepheid).
A new test that enables diagnosis of hepatitis C infection in a single visit could improve access to early diagnosis, monitoring, and treatment service for some of the most vulnerable people in Australia and the world.
Point-of-care hepatitis C virus (HCV) RNA testing offers an advantage over antibody testing, which only indicates previous exposure, enabling diagnosis of active infection in a single visit. The performance of a HCV Viral Load assay with venipuncture and finger-stick capillary whole-blood samples has been evaluated.
Scientists at the Kirby Institute collected plasma and finger-stick capillary whole-blood samples from participants in an observational cohort enrolled at five sites in Australia, three drug and alcohol clinics, one homelessness service, and one needle and syringe program. Of 210 participants enrolled between February 8, 2016, and July 27, 2016, 150 participants had viral load testing results for the three assays tested.
The scientists compared the sensitivity and specificity of the Xpert HCV Viral Load test for HCV RNA detection by venipuncture and finger-stick collection with their gold standard, the Abbott RealTime HCV Viral Load assay. The Xpert HCV Viral Load test is a quantitative test for rapid measurement of Hepatitis C virus Viral Load and confirmation of HCV infection delivers on-demand results in less than two hours.
HCV RNA was detected in 45 (30%) of 150 participants based on the Abbott RealTime assay. Sensitivity of the Xpert HCV Viral Load assay for HCV RNA detection in plasma collected by venipuncture was 100% and specificity was 99.1%. Sensitivity of the Xpert HCV Viral Load assay for HCV RNA detection in samples collected by finger-stick was 95.5% and specificity was 98.1%. No adverse events caused by the index test or the reference standard was observed. The authors concluded that the Xpert HCV Viral Load test can detect active infection from a finger-stick sample, which represents an advance over antibody-based tests that only indicate past or previous exposure.
Jason Grebely, PhD, an Associate Professor and lead author of the study, said, “Requiring people to come back for a second appointment to receive their results can present significant barriers, especially for people living in remote areas and for vulnerable and marginalized populations like homeless people and people who inject drugs, who are the people we need to reach the most in order to eliminate hepatitis C.” The study was published on April 21, 2017, in the journal The Lancet Gastroenterology & Hepatology.
Point-of-care hepatitis C virus (HCV) RNA testing offers an advantage over antibody testing, which only indicates previous exposure, enabling diagnosis of active infection in a single visit. The performance of a HCV Viral Load assay with venipuncture and finger-stick capillary whole-blood samples has been evaluated.
Scientists at the Kirby Institute collected plasma and finger-stick capillary whole-blood samples from participants in an observational cohort enrolled at five sites in Australia, three drug and alcohol clinics, one homelessness service, and one needle and syringe program. Of 210 participants enrolled between February 8, 2016, and July 27, 2016, 150 participants had viral load testing results for the three assays tested.
The scientists compared the sensitivity and specificity of the Xpert HCV Viral Load test for HCV RNA detection by venipuncture and finger-stick collection with their gold standard, the Abbott RealTime HCV Viral Load assay. The Xpert HCV Viral Load test is a quantitative test for rapid measurement of Hepatitis C virus Viral Load and confirmation of HCV infection delivers on-demand results in less than two hours.
HCV RNA was detected in 45 (30%) of 150 participants based on the Abbott RealTime assay. Sensitivity of the Xpert HCV Viral Load assay for HCV RNA detection in plasma collected by venipuncture was 100% and specificity was 99.1%. Sensitivity of the Xpert HCV Viral Load assay for HCV RNA detection in samples collected by finger-stick was 95.5% and specificity was 98.1%. No adverse events caused by the index test or the reference standard was observed. The authors concluded that the Xpert HCV Viral Load test can detect active infection from a finger-stick sample, which represents an advance over antibody-based tests that only indicate past or previous exposure.
Jason Grebely, PhD, an Associate Professor and lead author of the study, said, “Requiring people to come back for a second appointment to receive their results can present significant barriers, especially for people living in remote areas and for vulnerable and marginalized populations like homeless people and people who inject drugs, who are the people we need to reach the most in order to eliminate hepatitis C.” The study was published on April 21, 2017, in the journal The Lancet Gastroenterology & Hepatology.
Latest Technology News
- New qPCR Master Mixes Offer Broad Compatibility for Routine Research
- Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
- Personal PCR Analyzer Aims to Enable At-Home Infectious Disease Testing
- Microfluidic Assay Predicts Treatment Response in Pediatric Leukemia
- AI Models Use Routine Blood Tests and Health Records to Predict Cancer Risk
- Compact PCR Thermal Cycler Launches for Routine Molecular Laboratory Workflows
- New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows
- Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
- Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
- New Automation Workflow Streamlines NGS Library Preparation for High-Volume Labs
- ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
- Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
- New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
- Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
- Autonomous Robotic System Receives FDA Authorization for Blood Collection
- Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Channels
Clinical Chemistry
view channel
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreMolecular Diagnostics
view channel
Multimodal AI Blood Test Aims to Improve Early Lung Cancer Screening
Lung cancer screening can detect stage 1 disease, but false-positive findings, repeated follow-up, and radiation exposure remain important concerns. Current NHS screening is limited to current and former... Read more
FDA Clears Three-Virus Respiratory Panel for Anterior Nasal Swabs
Influenza and respiratory syncytial virus (RSV) often circulate during the same season and cause overlapping symptoms, making accurate differentiation important for clinical management. Seasonal testing... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians
Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







